Coronavirus (COVID-19) Collection
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
Since December 2019, COVID-19 caused by SARS-CoV-2 has spread worldwide (Hayakawa et al., 2020). As of January 25th, 2022, 544 re-infected COVID-19 cases have been reported worldwide (BNO news. 2022; Inada et al., 2021).A case of varicella zoster virus meningitis following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
Since December 2019, COVID-19, caused by SARS-CoV-2 infection, has been a major health threat worldwide (Hayakawa et al., 2020). The mRNA-based BNT162b2 mRNA COVID-19 vaccine has demonstrated a high efficacy rate with an acceptable safety profile (Polack et al., 2020). In Japan, a nationwide mass BNT162b2 mRNA vaccination campaign was launched and rolled out at an exceptionally rapid pace with high vaccine acceptance. As of June 13, 2021, 14.0% (n=17 580 587) and 4.9% (n=6 104 732) of the population had received their first and second vaccine dose, respectively (Ministry of Health, Labour and Welfare, Japan, 2021).Periungual desquamation in a Japanese Adult recovering from severe COVID-19
A 50-year-old Japanese man was admitted to our hospital with a 14-day history of fever and sudden dyspnea. The patient was diagnosed with severe coronavirus disease (COVID-19) based on positive test results of RNA polymerase chain reaction for severe acute respiratory syndrome coronavirus. He was started on mechanical ventilation and extracorporeal membrane oxygenation (ECMO). He received ECMO for 23 days and was tracheostomized on hospital day (HD) 37. His general condition improved by HD 54. On HD 61, periungual desquamation appeared on the fingers of left hand (Panel 1A), left palm (Panel 1B), and both feet (Panel 1C).
